MedTrace Logo

Evaluation of Point-of-care Tests for the Diagnosis of Cutaneous Leishmaniasis in Afghanistan

NCT03435419 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 274

Last updated 2018-02-19

No results posted yet for this study

Summary

New point-of-care (POC) tests are needed and assessing the performance of these tests for cutaneous leishmaniasis (CL) in Afghanistan may help increasing the number of CL patients with access to accurate diagnosis, and enable prompt treatment. Simpler tests could improve treatment access and benefit patients and communities, by reducing the risk of sequelae and the risk of disease transmission. CLeishPOCAFG aims to advance the diagnosis of CL by using more accurate and field-amenable methods.

Conditions

  • Cutaneous Leishmaniases

Interventions

DIAGNOSTIC_TEST

LoopampTM Leishmania Detection Kit

LoopampTM Leishmania Detection Kit is a diagnostic test for Leishmania DNA detection

DIAGNOSTIC_TEST

CL DetectTM Rapid Test

CL DetectTM Rapid Test is a diagnostic test for Leishmania antigen detection

Sponsors & Collaborators

  • Foundation for Innovative New Diagnostics, Switzerland

    lead OTHER

Principal Investigators

  • Martijn Vink, MD, MPH · HealthNet TPO

  • Israel Cruz, PhD · Foundation for Innovative New Diagnostics

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-16
Primary Completion
2016-06-22
Completion
2016-07-18

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03435419 on ClinicalTrials.gov